CRLCHARLES RIVER LABORATORIES ...

NYSE criver.com


$ 227.71 $ -1.97 (-0.86 %)    

Friday, 10-May-2024 15:59:33 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 228.12
$ 230.20
$ 0.00 x 0
$ 0.00 x 0
$ 223.95 - $ 230.74
$ 161.65 - $ 275.00
842,499
na
11.83B
$ 1.34
$ 26.61
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-30-2024 10-Q
2 02-14-2024 12-30-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 07-01-2023 10-Q
5 05-11-2023 04-01-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-02-2022 09-24-2022 10-Q
8 08-03-2022 06-25-2022 10-Q
9 05-04-2022 03-26-2022 10-Q
10 02-16-2022 12-25-2021 10-K
11 11-03-2021 09-25-2021 10-Q
12 08-04-2021 06-26-2021 10-Q
13 05-04-2021 03-27-2021 10-Q
14 02-17-2021 12-26-2020 10-K
15 11-09-2020 09-26-2020 10-Q
16 10-29-2020 09-26-2020 10-Q
17 08-05-2020 06-27-2020 10-Q
18 05-07-2020 03-28-2020 10-Q
19 02-11-2020 12-28-2019 10-K
20 11-06-2019 09-28-2019 10-Q
21 07-31-2019 06-29-2019 10-Q
22 05-07-2019 03-30-2019 10-Q
23 02-13-2019 12-29-2018 10-K
24 11-07-2018 09-29-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 02-13-2018 12-30-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-09-2017 07-01-2017 10-Q
30 05-10-2017 04-01-2017 10-Q
31 02-14-2017 12-31-2016 10-K
32 11-02-2016 09-24-2016 10-Q
33 08-03-2016 06-25-2016 10-Q
34 05-04-2016 03-26-2016 10-Q
35 02-12-2016 12-26-2015 10-K
36 11-04-2015 09-26-2015 10-Q
37 07-30-2015 06-27-2015 10-Q
38 04-30-2015 03-28-2015 10-Q
39 02-17-2015 12-27-2014 10-K
40 10-30-2014 09-27-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-outperform-on-charles-river-lowers-price-target-to-270

Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and lowers the price target from $282 to $270.

 charles-river-laboratories-reaffirms-outlook-for-fy24-revenue-growth-of-10-40-and-adj-eps-of-1090-1140-est-1102

 Despite modest adjustments to the quarterly gating in 2024, the Company's outlook for the year remains essentially unchang...

 charles-river-q1-2024-adj-eps-227-beats-207-estimate-sales-1011b-beat-992270m-estimate

Charles River (NYSE:CRL) reported quarterly earnings of $2.27 per share which beat the analyst consensus estimate of $2.07 by 9...

 charles-river-launches-viral-vector-reference-materials-to-streamline-the-transition-to-gmp

Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developersCharles Ri...

Core News & Articles

This agreement comes ahead of entering into an anticipated master services agreement for the development and manufacture of Fib...

 charles-river-to-perform-plasmid-production-for-ship-of-theseus

GMP grade plasmid DNA to serve as a direct therapeutic targeting various indicationsCharles River Laboratories International, I...

 argus-research-maintains-buy-on-charles-river-raises-price-target-to-290

Argus Research analyst David Toung maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $200 to $290.

 charles-river-and-navega-therapeutics-announce-comprehensive-gene-therapy-manufacturing-collaboration

Next-generation AAV gene therapy to target debilitating pain disorders Charles River Laboratories International, Inc. (NYSE:CR...

 wheeler-bio-taps-charles-river-to-offer-portable-cmc-to-discovery-clients-to-accelerate-their-journey-to-first-in-human-use

Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreeme...

 charles-river-and-wheeler-bio-complete-agreement-to-accelerate-the-journey-from-discovery-and-cmc-development-to-manufacturing

 Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic agreement with Wheeler Bio, Inc., an ant...

 charles-river-collaborates-with-pluristyx-expanding-its-portfolio-of-human-pluripotent-stem-cells

The addition of ES cells and iPSCs will enhance Charles River's portfolio of powerful research tools supporting acceleratio...

 guggenheim-downgrades-charles-river-to-neutral

Guggenheim analyst Sandy Draper downgrades Charles River (NYSE:CRL) from Buy to Neutral.

 stocks-rebound-as-investor-focus-shifts-to-earnings-bitcoin-tops-1-trillion-value-whats-driving-markets-wednesday

The U.S. stock market attempted a rebound following Tuesday’s declines, which were sparked by a higher-than-expected inflation ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION